Why ppl deny KEY factors, and Key references is ******g beyond me.
References
1.
European Medicines Agency (EMA). COVID-19 mRNA vaccines Comirnaty and Spikevax: risk of myocarditis pericarditis. Published online July 19, 2021. Accessed November 9, 2021.
COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis pericarditis - European Medicines Agency
2.
Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel.
N Engl J Med. Published online October 6, 2021. doi:
10.1056/NEJMoa2109730
3.
Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization.
N Engl J Med. Published online October 6, 2021. doi:
10.1056/NEJMoa2110737
4.
Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination.
JAMA. 2021;326(14):1390-1399. doi:
10.1001/jama.2021.15072
ArticlePubMedGoogle ScholarCrossref
5.
Centers for Disease Control and Prevention Advisory Committee on Immunization Practices meeting. Myocarditis analyses in the vaccine safety datalink: rapid cycle analyses and “head-to-head” product comparisons. October 21, 2021. Accessed March 10, 2022.
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/08-COVID-Klein-508.pdf
6.
Montgomery J, Ryan M, Engler R, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military.
JAMA Cardiol. 2021;6(10):1202-1206. doi:
10.1001/jamacardio.2021.2833
ArticlePubMedGoogle ScholarCrossref
7.
Centers for Disease Control and Prevention Advisory Committee on Immunization Practices meeting. Myopericarditis following COVID-19 vaccination: updates from the Vaccine Adverse Event Reporting System (VAERS). October 21, 2021. Accessed March 10, 2022.
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/07-COVID-Su-508.pdf
8.
US Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting. Surveillance updates of myocarditis/pericarditis and mRNA COVID-19 vaccination in the FDA BEST System. October 14, 2021. Accessed March 10, 2022.
https://www.fda.gov/media/153090/download
9.
Centers for Disease Control and Prevention Advisory Committee on Immunization Practices meeting. COVID-19 vaccine safety updates. October 21, 2021. Accessed March 10, 2022.
https://www.cdc.gov/vaccines/acip/m...es-2021-10-20-21/06-COVID-Shimabukuro-508.pdf
10.
Government of Ontario. Canada. Ontario recommends the use of Pfizer-BioNTech COVID-19 vaccine for individuals aged 18-24 years old. Published online September 29, 2021. Accessed September 29, 2021.
Ontario Newsroom
11.
EPI-PHARE. Myocardite et péricardite après la vaccination Covid-19 [in French]. Published online November 8, 2021. Accessed November 9, 2021.
Myocardite et péricardite après la vaccination Covid-19
12.
Ljung R, Sundström A, Grünewald M, et al. The profile of the Covid-19 vaccination register safety study in Sweden (CoVacSafe-SE).
Ups J Med Sci. 2021;126. doi:
10.48101/ujms.v126.8136 PubMedGoogle Scholar
13.
Laugesen K, Ludvigsson JF, Schmidt M, et al. Nordic Health Registry–based research: a review of health care systems and key registries.
Clin Epidemiol. 2021;13:533-554. doi:
10.2147/CLEP.S314959 PubMedGoogle ScholarCrossref
14.
Ludvigsson JF, Håberg SE, Knudsen GP, et al. Ethical aspects of registry-based research in the Nordic countries.
Clin Epidemiol. 2015;7:491-508. doi:
10.2147/CLEP.S90589 PubMedGoogle Scholar
15.
Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
N Engl J Med. 2021;384(22):2124-2130. doi:
10.1056/NEJMoa2104882 PubMedGoogle ScholarCrossref
16.
Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
BMJ. 2021;373(1114):n1114. doi:
10.1136/bmj.n1114 PubMedGoogle Scholar
17.
Sera F, Armstrong B, Blangiardo M, Gasparrini A. An extended mixed-effects framework for meta-analysis.
Stat Med. 2019;38(29):5429-5444. doi:
10.1002/sim.8362 PubMedGoogle ScholarCrossref
18.
R Core Team. The R Project for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria; 2021. Accessed November 9, 2021.
https://www.r-project.org
19.
Cochran WG. The comparison of percentages in matched samples.
Biometrika. 1950;37(3-4):256-266. doi:
10.1093/biomet/37.3-4.256 PubMedGoogle ScholarCrossref
20.
US Food and Drug Administration. Spikevax. February 18, 2022. Accessed February 21, 2022.
SPIKEVAX
21.
US Food and Drug Administration. Comirnaty (previously COVID-19 vaccine Moderna). December 16, 2021. Accessed February 21, 2022.
(COVID-19 Vaccine, mRNA)
22.
European Medicines Agency. Spikevax (previously COVID-19 vaccine Moderna). February 21, 2022. Accessed February 12, 2022.
Spikevax (previously COVID-19 Vaccine Moderna) - European Medicines Agency
23.
European Medicines Agency (EMA). Comirnaty. February 16, 2022. Accessed February 21, 2022.
Comirnaty - European Medicines Agency
24.
American College of Cardiology. Perspectives: vaccine-associated myocarditis risk in context: emerging evidence. February 9, 2022. Accessed February 21, 2022.
Vaccine-Associated Myocarditis Risk in Context: Emerging Evidence - American College of Cardiology
25.
World Health Organization. WHO coronavirus (COVID-19) dashboard. Accessed February 16, 2022.
https://covid19.who.int
26.
Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.
N Engl J Med. 2022. Published online March 2, 2022. doi:
10.1056/NEJMoa2119451PubMedGoogle Scholar
27.
Bager P, Wohlfahrt J, Bhatt S, et al. Reduced risk of hospitalisation associated with infection with SARS-CoV-2 Omicron relative to Delta: a Danish cohort study.
Lancet. Published online January 14, 2022. doi:
10.2139/ssrn.4008930Google Scholar
28.
Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households.
medRxiv. Preprint posted online January 30, 2022. doi:
10.1101/2022.01.28.22270044Google Scholar
29.
Ioannou GN, Locke ER, Green PK, Berry K. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: a target trial emulation study in the U.S. Veterans Affairs healthcare system.
EClinicalMedicine. 2022;45:101326. doi:
10.1016/j.eclinm.2022.101326PubMedGoogle Scholar
30.
Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in US veterans.
N Engl J Med. 2022;386(2):105-115. doi:
10.1056/NEJMoa2115463 PubMedGoogle ScholarCrossref
31.
Dagan N, Barda N, Balicer RD. Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex.
N Engl J Med. 2021;385(24):2299. doi:
10.1056/NEJMc2115045PubMedGoogle ScholarCrossref
32.
Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting.
N Engl J Med. 2021;385(12):1078-1090. doi:
10.1056/NEJMoa2110475 PubMedGoogle ScholarCrossref
33.
Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
Nat Med. 2022;28(2):410-422. doi:
10.1038/s41591-021-01630-0PubMedGoogle ScholarCrossref
34.
Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
BMJ. 2021;375:e068665. doi:
10.1136/bmj-2021-068665 PubMedGoogle Scholar